



# HOKKAIDO UNIVERSITY

|                  |                                                                                                                                                                                                          |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title            | Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team                                                  |
| Author(s)        | Kagami, Keisuke; Ishiguro, Nobuhisa; Yamada, Takehiro et al.                                                                                                                                             |
| Citation         | American Journal of Infection Control, 49(12), 1493-1498<br><a href="https://doi.org/10.1016/j.ajic.2021.08.011">https://doi.org/10.1016/j.ajic.2021.08.011</a>                                          |
| Issue Date       | 2021-12                                                                                                                                                                                                  |
| Doc URL          | <a href="https://hdl.handle.net/2115/87379">https://hdl.handle.net/2115/87379</a>                                                                                                                        |
| Rights           | © 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license<br><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> |
| Rights(URL)      | <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>                                                                                      |
| Type             | journal article                                                                                                                                                                                          |
| File Information | Kagami K et al. Am. J. Infect. Control 49, 1493-8, 2021.pdf                                                                                                                                              |



Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant  
*Staphylococcus aureus* antibiotics by an antimicrobial stewardship team

Keisuke Kagami, Ph.D.<sup>a,b</sup>, Nobuhisa Ishiguro, M.D., Ph.D.<sup>b</sup>, Takehiro Yamada, Ph.D.<sup>a,b</sup>,  
<sup>1</sup>, Yusuke Niinuma, B.S.<sup>a,b</sup>, Sumio Iwasaki, B.S.<sup>b,c</sup>, Keisuke Taki, M.S.<sup>b,c</sup>, <sup>2</sup>, Tatsuya  
Fukumoto, Ph.D.<sup>b,c</sup>, Kasumi Hayasaka<sup>b,c</sup>, Mutsumi Nishida, Ph.D.<sup>c</sup>, Junichi Sugita,  
M.D., Ph.D.<sup>c,d</sup>, Takanori Teshima, M.D., Ph.D.<sup>c,d</sup>, Mitsuru Sugawara, Ph.D.<sup>a,e</sup>, Yoh  
Takekuma, Ph.D.<sup>a,\*</sup>

<sup>a</sup>Department of Pharmacy, Hokkaido University Hospital; Kita-14-jo, Nishi-5-chome,  
Kita-ku, Sapporo 060-8648, Japan

<sup>b</sup>Department of Infection Control and Prevention, Hokkaido University Hospital;  
Kita-14-jo, Nishi-5-chome, Kita-ku, Sapporo 060-8648, Japan

<sup>c</sup>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital;  
Kita-14-jo, Nishi-5-chome, Kita-ku, Sapporo 060-8648, Japan

<sup>d</sup>Department of Hematology, Faculty of Medicine, Hokkaido University; Kita-15-jo,  
Nishi-7-chome, Kita-ku, Sapporo 060-8638, Japan

<sup>e</sup>Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido

University; Kita-12-jo, Nishi-6-chome, Kita-ku, Sapporo 060-0812, Japan

<sup>1</sup>Current institution;

Faculty of Pharmacy, Hokkaido University of Science; 7-Jo, 15-4-1 Maeda, Teine,  
Sapporo 006-8585, Japan

<sup>2</sup>Current institution;

Department of Clinical Laboratory, Sapporo Teishinkai Hospital; 3-1, Kita-33-jo,  
Higashi-1-chome, Higashi-ku, Sapporo 065-0033, Japan

\*Corresponding Author

Yoh Takekuma, Ph.D.

Department of Pharmacy, Hokkaido University Hospital; Kita-14-jo, Nishi-5-chome,  
Kita-ku, Sapporo 060-8648, Japan

Tel: +81-11-706-5754; Fax: +81-11-706-7616; E-mail:y-kuma@pharm.hokudai.ac.jp

## **Conflict of Interest**

All authors have no known competing financial interests or personal relationships that

could have appeared to influence the work reported in this paper.

#### **Abstract**

*Background:* There are no reports on the effects of interventions, such as discontinuation and change/de-escalation of carbapenems and anti-methicillin-resistant *Staphylococcus aureus* (MRSA) antibiotics by an antimicrobial stewardship team focusing on detailed patient outcomes. This study aimed to evaluate these effects.

*Methods:* This retrospective cohort study was conducted at a tertiary care hospital from December 2018 to November 2019.

*Results:* Favorable clinical responses were obtained in 165/184 cases (89.7%) in the intervention-accepted group, higher than those in the not accepted group (14/19 cases, 73.7%;  $P=0.056$ ). All-cause 30-day mortality was lower in the accepted group than in the not accepted group (1.1% and 10.5%, respectively;  $P=0.045$ ). The microbiological outcomes were similar between the two groups. Duration of carbapenem and anti-MRSA antibiotic use in the accepted group was significantly lower than that in the not accepted group (median [interquartile range]: 8 days [5-13] versus 14 days [8-15], respectively,  $P=0.026$  for carbapenem; 10 days [5.3-15] versus 15.5 days [13.8-45.3], respectively,  $P=0.014$  for anti-MRSA antibiotic).

1        *Conclusion:* This is the first study to investigate the effects of interventions such as  
2        discontinuation and change/de-escalation of antibiotics on detailed outcomes. Our  
3        intervention could reduce the duration of carbapenem and anti-MRSA antibiotic use  
4        without worsening clinical and microbiological outcomes.

5  
6        **Keywords:** Antimicrobial stewardship team; Carbapenem; Methicillin-resistant  
7        *Staphylococcus aureus*; Outcome; Antibiotic use

8  
9  
10       **Highlights**

11       Carbapenem and anti-MRSA antibiotic intervention showed 89.7% favorable outcome.

12       Carbapenem and anti-MRSA antibiotic intervention could reduce the antibiotic uses.

13       Discontinuation and de-escalation of antibiotics did not worsen clinical outcomes.

14  
15  
16  
17  
18       **Introduction**

19       Increasing antibiotic consumption has become a critical global issue.<sup>1-3</sup> The  
20       unnecessary and inappropriate use of antibiotics has led to the emergence of resistant  
21       bacteria, thereby creating difficulty in treating infections.<sup>1-3</sup> Antibiotic resistance extends

hospital stay and increases medical costs.<sup>3</sup> In addition, unnecessary antibiotic use also increases medical expenditure.<sup>2</sup>

To solve these problems, implementation of antimicrobial stewardship programs (ASP) has been recommended.<sup>4-7</sup> The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines have recommended “formulary restriction and pre-authorization” and “prospective audit and feedback (PAF)” as strategies of ASP.<sup>4,5</sup> Several studies have reported that implementation of ASP promotes appropriate antibiotic use,<sup>8-10</sup> prevents or delays emergence of resistant bacteremia,<sup>11-15</sup> and reduces hospital stay<sup>12,16,17</sup> and medical expenditure.<sup>18-20</sup>

Some studies have demonstrated the efficacy and safety of ASP by evaluating the relationship between antibiotic use and clinical outcomes. For example, ASP, including recommendations for antibiotic discontinuation and change, reduced both antibiotic use and length of hospital stay.<sup>7</sup> In addition, intervention for meropenem<sup>21</sup> or broad-spectrum antibiotics<sup>22</sup> decreased the use of antibiotics without increasing mortality. However, most studies on ASP have evaluated outcomes by 30-day mortality or length of hospital stay and have not investigated individual detailed clinical and microbiological outcomes.<sup>7,16,22</sup>

To our knowledge, there are no reports on the effects of interventions, such as

1 discontinuation and change/de-escalation of carbapenems and anti-methicillin-resistant  
2 *Staphylococcus aureus* (MRSA) antibiotics, focusing on individual clinical response and  
3 microbiological outcomes. The present study aimed to evaluate the effects of intervention  
4 for these antibiotics on the detailed clinical and microbiological outcomes and duration of  
5 antibiotic use.

## 6 7 **Patients and methods**

### 8 9 *Study Design and intervention*

10 This retrospective cohort study was conducted at a 939-bed tertiary care medical  
11 center. The study protocol was approved by the ethics committee of the institution where  
12 the present study was conducted (Institutional Review Board number: 019-0120) and  
13 was performed in accordance with the Declaration of Helsinki. The requirement for  
14 informed consent was waived because of the retrospective observational nature of the  
15 study. This study was conducted using the opt-out method on our hospital website. Data  
16 of patients treated with carbapenems and/or anti-MRSA antibiotics between December  
17 2018 and November 2019 were obtained for the present study from the medical charts.

18 Antimicrobial stewardship team (AST) pharmacists reviewed all cases where

carbapenem and/or anti-MRSA antibiotic were used, with a focus on their doses, duration of use, culture results, infection sites, therapeutic effects, and adverse effects. The reviews were performed from the start of treatment with the target antibiotics on weekdays. The reviewed carbapenems included meropenem, doripenem, and imipenem/cilastatin, which are intravenous carbapenems administered in our hospital. The reviewed anti-MRSA antibiotics included vancomycin, teicoplanin, linezolid, tedizolid, daptomycin, and arbekacin. Oral antibiotics linezolid and tedizolid were also reviewed. Data from patients admitted to the intensive care unit (ICU) were excluded from the review because our restriction and review systems were applied to patients in general wards.

Inappropriate use of antibiotics found on the pharmacist's review was discussed with AST members. The AST physician contacted prescribing physicians about the inappropriate use and made suggestions, such as discontinuation, change of antibiotic, de-escalation, change in dosage, addition of antibiotics, and/or addition of examination (blood, bacterial, and imaging tests). In addition to these suggestions, we checked the patients' status and/or provided information, such as side effects, to the physician. The status of patients identified in our review was checked by discussions with the prescribing physicians; there were no suggestions. These reviews and interventions, i. e.

PAF, were performed every weekday.

In our ASP, antibiotic discontinuation was recommended when the course of therapy, defined by guidelines, such as the Sanford guide to antimicrobial therapy,<sup>23</sup> was completed, and further antibiotic treatment was considered unnecessary due to sufficient improvement. De-escalation was recommended based on bacterial information, including minimum inhibitory concentrations, according to the following criteria: (1) severity was clinically improved, (2) other infection sites were excluded, and (3) febrile neutropenia was not continued.<sup>24</sup> Changes in antibiotics, such as change in anti-MRSA antibiotics, were recommended based on bacterial information or development of side effects, such as renal failure, thrombocytopenia, or increased levels of creatine kinase.

#### *Data collection*

The following data during the study period were extracted from the medical charts: age, sex, admission to the intensive care unit (ICU), surgery within 30 days, Sequential Organ Failure Assessment (SOFA) score, underlying disease, site of infection, concomitant drugs, whole blood cells (WBC), C-reactive protein (CRP), body temperature (BT), length of hospital stay, duration of antibiotic treatment, and bacterial information.

1

## 2 *Definition of outcome*

3       A favorable clinical response was defined as the resolution or partial resolution of the  
4     presenting symptoms and signs of infection. Clinical failure was defined as the  
5     persistence or worsening of symptoms and/or signs of infection. The clinical response  
6     was evaluated based on leukocytosis, inflammation, fever, and local signs.  
7     Microbiological persistence was defined as persistent detection of the same  
8     microorganisms and sources during antibiotic therapy. Microbiological recurrence was  
9     defined as the detection of the same microorganisms and sources within 30 days after  
10    discontinuation of antibiotic therapy. The outcomes were compared between the groups  
11    where the AST recommendation was accepted and that was not accepted.

12

## 13 *Statistical analysis*

14       In the statistical analyses of the characteristics and patient outcomes, categorical  
15     variables were compared using Fisher's exact test, and continuous variables were  
16     compared using the Mann-Whitney *U* test. Changes in WBC, CRP, and BT data were  
17     compared using Wilcoxon signed-rank test. Statistical significance was set at  $P < 0.05$ .  
18     The calculations were performed using JMP Pro version 14 (SAS Institute Inc., Japan) or

GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA, USA).

## Results

### *Intervention*

During the study period, the total number of patients treated with carbapenem was 673 (Table 1). Among these cases, we performed interventions for 144 cases (21.4%) and made recommendations for 98 cases, of which 89 (90.8%) were accepted. With regard to anti-MRSA antibiotics, the total number of patients was 710. We performed interventions in 195 cases (27.5%). Among them, we made recommendations for 146 cases and 136 cases (93.2 %) were accepted.

1 Table 1 Intervention for carbapenem and anti-MRSA antibiotic uses by AST.

2

| Interventions                      | Carbapenem use |        |              | Anti-MRSA antibiotic use |        |                |
|------------------------------------|----------------|--------|--------------|--------------------------|--------|----------------|
|                                    | (n=673)        |        |              | (n=710)                  |        |                |
|                                    | Intervention   |        | Accepted     | Intervention             |        | Accepted       |
|                                    | n              | (%)    | (%)          | n                        | (%)    | (%)            |
| Recommendation                     |                |        |              |                          |        |                |
| Choice of antibiotic               |                |        |              |                          |        |                |
| Discontinuation of antibiotic      | 39             | (5.8)  | 92.3         | 50                       | (7)    | 92.0           |
| Change/de-escalation of antibiotic | 47             | (7)    | 87.2         | 34                       | (4.8)  | 88.2           |
| Addition of antibiotic             | 0              | (0)    | -            | 13                       | (1.8)  | 100            |
| Dose adjustment                    |                |        |              |                          |        |                |
| Increase of dosage                 | 6              | (0.9)  | 100          | 9                        | (1.3)  | 77.8           |
| Decrease of dosage                 | 0              | (0)    | -            | 5                        | (0.7)  | 100            |
| Others                             |                |        |              |                          |        |                |
| Recommendation of TDM              | -              | -      | -            | 16                       | (2.3)  | 100            |
| Addition of examination            | 5              | (0.7)  | 100          | 17                       | (2.4)  | 100            |
| Others                             | 1              | (0.2)  | 100          | 2                        | (0.3)  | 100            |
| Checking patients' status          | 39             | (5.8)  | -            | 42                       | (5.9)  | -              |
| Providing information              | 7              | (1)    | -            | 7                        | (1)    | -              |
| Total                              | 144            | (21.4) | 89/98 (90.8) | 195                      | (27.5) | 136/146 (93.2) |

3

4 Abbreviations: AST, antimicrobial stewardship team; MRSA, methicillin-resistant

5 *Staphylococcus aureus*; TDM, therapeutic drug monitoring.

6

## *Population*

Table 2 shows characteristics of the patients in which AST recommendation was done during the study period. In the analysis of the effect of our ASP, AST recommendations included the choice of antibiotic and dose adjustment and excluded elements, such as recommendation of TDM or examination, because the recommendation of TDM and examinations were considered to be indirectly associated with clinical outcome. Characteristics of patients between accepted and not accepted groups were almost similar except for the proportion of hematological malignancy, febrile neutropenia, and concomitant therapy.

1 Table 2 Characteristics of the patients in which AST recommendation<sup>a</sup> was done.

2

| Characteristic                           | Accepted<br>(n=184) | Not accepted<br>(n=19) | P value |
|------------------------------------------|---------------------|------------------------|---------|
| Age (year)                               | 62 (43.5-71)        | 61 (55-65)             | 0.43    |
| Sex (Men)                                | 106 (57.6)          | 9 (47.4)               | 0.468   |
| Admission to ICU within previous 30 days | 43 (23.4)           | 1 (5.3)                | 0.081   |
| Surgery within previous 30 days          | 57 (31)             | 3 (15.8)               | 0.197   |
| SOFA score                               | 2 (1-4)             | 4 (1-9)                | 0.064   |
| Underlying condition                     |                     |                        |         |
| Hypertension                             | 40 (21.7)           | 7 (36.8)               | 0.156   |
| Diabetes mellitus                        | 25 (13.6)           | 3 (15.8)               | 0.731   |
| Cardiovascular disease                   | 48 (26.1)           | 2 (10.5)               | 0.169   |
| Respiratory failure                      | 17 (9.2)            | 2 (10.5)               | 0.694   |
| COPD                                     | 2 (1.1)             | 1 (5.3)                | 0.257   |
| Chronic renal insufficiency              | 15 (8.2)            | 2 (10.5)               | 0.664   |
| Liver disease                            | 19 (10.3)           | 3 (15.8)               | 0.441   |
| Hepatic cirrhosis                        | 7 (3.8)             | 0 (0)                  | 1       |
| Urogenital disorders                     | 4 (2.2)             | 0 (0)                  | 1       |
| Cerebrovascular disease                  | 24 (13)             | 2 (10.5)               | 1       |
| HIV infection                            | 1 (0.5)             | 0 (0)                  | 1       |
| Hematological malignancy                 | 20 (10.9)           | 9 (47.4)               | <0.001  |
| Solid malignancy                         | 77 (41.8)           | 5 (26.3)               | 0.226   |
| Transplantation (solid)                  | 8 (4.3)             | 0 (0)                  | 1       |
| Infection                                |                     |                        |         |
| Intra-abdominal infection                | 59 (32.1)           | 4 (21.1)               | 0.438   |
| Catheter-related blood stream infection  | 32 (17.4)           | 3 (15.8)               | 1       |
| Urinary tract infection                  | 21 (11.4)           | 3 (15.8)               | 0.477   |
| Soft tissue infection                    | 19 (10.3)           | 0 (0)                  | 0.226   |
| Febrile neutropenia                      | 10 (5.4)            | 5 (26.3)               | 0.007   |
| Osteomyelitis                            | 13 (7.1)            | 0 (0)                  | 0.616   |
| Respiratory tract infection              | 9 (4.9)             | 3 (15.8)               | 0.089   |

|                                                                       |            |          |       |
|-----------------------------------------------------------------------|------------|----------|-------|
| Blood stream infection                                                | 7 (3.8)    | 0 (0)    | 1     |
| Central nervous system infection                                      | 5 (2.7)    | 1 (5.3)  | 0.45  |
| Others                                                                | 6 (3.3)    | 0 (0)    | 1     |
| Cardiovascular infections                                             | 3 (1.6)    | 0 (0)    | 1     |
| Concomitant therapy                                                   |            |          |       |
| Monotherapy                                                           | 103 (56)   | 5 (26.3) | 0.016 |
| Bi-therapy                                                            | 49 (26.6)  | 5 (26.3) | 1     |
| Three-therapy                                                         | 26 (14.1)  | 7 (36.8) | 0.019 |
| Four-therapy                                                          | 4 (2.2)    | 2 (10.5) | 0.099 |
| Five-therapy                                                          | 1 (0.5)    | 0 (0)    | 1     |
| Six-therapy                                                           | 1 (0.5)    | 0 (0)    | 1     |
| Days from start of carbapenem or anti-MRSA antibiotic to intervention | 6 (2-11.8) | 6 (4-9)  | 0.721 |

1

2 Data are presented as numbers (%) or medians (interquartile ranges).

3 <sup>a</sup> Recommendation includes choice of antibiotic and dose adjustment and excludes others  
4 such as recommendation of therapeutic drug monitoring (TDM) and addition of  
5 examination.

6 Abbreviations: AST, antimicrobial stewardship team; ICU, intensive care unit; SOFA,  
7 Sequential Organ Failure Assessment; COPD, chronic obstructive pulmonary disease;  
8 HIV, human immunodeficiency virus; MRSA, methicillin-resistant *Staphylococcus*  
9 *aureus*.

1    *Intervention based on target bacteria*

2        Table 3 shows AST recommendations based on target bacteria. In intervention for  
3    carbapenem and anti-MRSA antibiotic uses, the most frequently conducted de-escalation  
4    was change to cefmetazole for *Escherichia coli* (including extended-spectrum  
5     $\beta$ -lactamase producing type) (7 cases) and change to cefazolin for methicillin-sensitive  
6    *Staphylococcus aureus* (4 cases), respectively. In intervention for anti-MRSA biotic use,  
7    in addition to de-escalation, change to other anti-MRSA antibiotic or addition of  
8    anti-MRSA antibiotic for methicillin-resistant coagulase-negative Staphylococci or  
9    *Corynebacterium* species were performed frequently.

1 Table 3 AST recommendation (change/de-escalation and addition of antibiotics) based on target bacteria.

2

| Bacteria                                        | n  | (%)    | Accepted (n=184)             |      |     |     |      |     |         |      | Not accepted (n=19) |                              |     |     |      |      |                          |
|-------------------------------------------------|----|--------|------------------------------|------|-----|-----|------|-----|---------|------|---------------------|------------------------------|-----|-----|------|------|--------------------------|
|                                                 |    |        | Changed/de-escalation to (n) |      |     |     |      |     |         |      | Addition<br><br>(n) | Changed/de-escalation to (n) |     |     |      |      |                          |
|                                                 |    |        | AMPC                         | ABPC | CEZ | CMZ | CTRX | CAZ | CPZ/SBT | CFPM |                     | Anti-MRSA<br>antibiotics     | CEZ | CMZ | CTRX | CFPM | Anti-MRSA<br>antibiotics |
|                                                 |    |        |                              |      |     |     |      |     |         |      |                     |                              |     |     |      |      |                          |
| Intervention for carbapenem use                 |    |        |                              |      |     |     |      |     |         |      |                     |                              |     |     |      |      |                          |
| MSSA                                            | 2  | (6.5)  |                              |      | 2   |     |      |     |         |      |                     |                              |     |     |      |      |                          |
| MSCNS                                           | 1  | (3.2)  |                              |      |     |     |      |     |         |      |                     | 1                            |     |     |      |      |                          |
| <i>Serratia marcescens</i>                      | 1  | (3.2)  |                              |      |     |     |      |     |         | 1    |                     |                              |     |     |      |      |                          |
| <i>Bacteroides fragilis</i>                     | 1  | (3.2)  |                              |      |     | 1   |      |     |         |      |                     |                              |     |     |      |      |                          |
| <i>Enterococcus faecalis</i>                    | 1  | (3.2)  | 1                            |      |     |     |      |     |         |      |                     |                              |     |     |      |      |                          |
| <i>Enterococcus gallinarum</i>                  | 1  | (3.2)  |                              |      |     |     |      |     |         |      | 1                   |                              |     |     |      |      |                          |
| <i>Escherichia coli</i>                         | 10 | (32.3) |                              |      | 4   | 4   | 1    |     |         | 1    |                     |                              |     |     |      |      |                          |
| <i>Escherichia coli</i> (ESBL)                  | 3  | (9.7)  |                              |      |     | 3   |      |     |         |      |                     |                              |     |     |      |      |                          |
| <i>Haemophilus influenzae</i> (β-lactamaze (-)) | 1  | (3.2)  |                              |      |     |     |      |     |         |      |                     |                              |     | 1   |      |      |                          |
| <i>Klebsiella pneumoniae</i>                    | 2  | (6.5)  |                              |      |     |     |      |     |         | 1    |                     |                              |     |     |      | 1    |                          |
| <i>Klebsiella pneumoniae</i> (ESBL)             | 2  | (6.5)  |                              |      |     | 1   |      |     |         |      |                     |                              | 1   |     |      |      |                          |
| <i>Peptostreptococcus</i> species               | 1  | (3.2)  |                              |      |     | 1   |      |     |         |      |                     |                              |     |     |      |      |                          |
| <i>Pseudomonas aeruginosa</i>                   | 5  | (16.1) |                              |      |     |     |      | 3   | 1       | 1    |                     |                              |     |     |      |      |                          |
| Total                                           | 31 | (100)  | 1                            |      | 6   | 10  | 1    | 3   | 1       | 4    | 1                   |                              | 1   | 1   | 1    | 1    |                          |

Intervention for anti-MRSA antibiotic use

|                                     |    |        |   |   |    |    |  |   |   |
|-------------------------------------|----|--------|---|---|----|----|--|---|---|
| MSSA                                | 4  | (8.7)  | 4 |   |    |    |  |   |   |
| MRSA                                | 3  | (6.5)  |   |   | 1  | 1  |  |   | 1 |
| MSCNS                               | 1  | (2.2)  | 1 |   |    |    |  |   |   |
| MRCNS                               | 20 | (43.5) |   |   | 15 | 5  |  |   |   |
| <i>Corynebacterium</i> species      | 11 | (23.9) |   |   | 5  | 6  |  |   |   |
| <i>Enterococcus faecalis</i>        | 1  | (2.2)  | 1 |   |    |    |  |   |   |
| <i>Enterococcus faecium</i>         | 4  | (8.7)  |   |   | 3  | 1  |  |   |   |
| <i>Enterococcus gallinarum</i>      | 1  | (2.2)  |   |   | 1  |    |  |   |   |
| <i>Klebsiella pneumoniae</i> (ESBL) | 1  | (2.2)  |   |   |    |    |  | 1 |   |
| Total                               | 46 | (100)  | 1 | 5 | 25 | 13 |  | 1 | 1 |

1

2 Abbreviations: AST, antimicrobial stewardship team; AMPC, amoxicillin; ABPC, ampicillin; CEZ, cefazolin; CMZ, cefmetazole; CTRX,  
3 ceftriaxone; CAZ, ceftazidime; CPZ/SBT, cefoperazone/sulbactam; CFPM, cefepime; MSSA, methicillin-susceptible *Staphylococcus aureus*;  
4 MRSA, methicillin-resistant *Staphylococcus aureus*; MSCNS: methicillin-susceptible coagulase-negative Staphylococci; MRCNS,  
5 methicillin-resistant coagulase-negative Staphylococci; ESBL, extended-spectrum  $\beta$ -lactamase.

6

1    *Changes in WBC, CRP, and BT*

2        In the accepted group, WBC, CRP, and BT were significantly decreased one week  
3    after the intervention ( $P < 0.001$ , respectively) (Table 4). In the not accepted group,  
4    although CRP and BT were numerically decreased one week after intervention, there  
5    were no significant differences.

6

7

Table 4 Changes in WBC, CRP, and BT of the patients in which AST recommendation<sup>a</sup> was done.

|                     | At the time of<br>intervention | 1 week after<br>intervention | P value |
|---------------------|--------------------------------|------------------------------|---------|
| Accepted (n=184)    |                                |                              |         |
| WBC (/μL)           | 7150 (4400-10100)              | 5800 (4200-8250)             | <0.001  |
| CRP (mg/dL)         | 2.5 (1.1-7.9)                  | 1.1 (0.4-3)                  | <0.001  |
| BT (°C)             | 37.1 (36.7-37.5)               | 36.8 (36.6-37.1)             | <0.001  |
| Not accepted (n=19) |                                |                              |         |
| WBC (/μL)           | 4800 (2275-7975)               | 6000 (3350-7150)             | 0.954   |
| CRP (mg/dL)         | 2.2 (0.9-5.3)                  | 0.8 (0.3-3.5)                | 0.202   |
| BT (°C)             | 37.5 (37-37.8)                 | 37.1 (36.8-37.6)             | 0.338   |

Data are presented as medians (interquartile ranges).

<sup>a</sup> Recommendation includes choice of antibiotic and dose adjustment and excludes others such as recommendation of therapeutic drug monitoring (TDM) and addition of examination.

Abbreviations: AST, antimicrobial stewardship team; WBC, whole blood cells; CRP, C-reactive protein; BT, body temperature.

## *Outcomes*

Favorable clinical responses were obtained in 165 out of 184 cases (89.7%) in the accepted group, which was higher than those in the not accepted group (14/19 cases, 73.7%;  $P=0.056$ ) (Table 5). In addition, all-cause 30-day mortality was lower in the accepted group than in the not accepted group (1.1% and 10.5%, respectively;  $P=0.045$ ). However, there was no significant difference in the infection-related 30-day mortality between the accepted and not accepted groups (0.5% and 0%, respectively;  $P=1$ ). The microbiological outcomes were similar between the two groups. The median length of hospital stay in the accepted and not accepted groups was 64 days (interquartile range [IQR] 44-134) and 88 days (IQR 48-171), respectively;  $P=0.538$ . Duration of carbapenem and anti-MRSA antibiotic use in the accepted group was significantly lower than that in the not accepted group (median [IQR], 8 days [5-13] versus 14 days [8-15], respectively;  $P=0.026$  for carbapenem and 10 days [5.3-15] versus 15.5 days [13.8-45.3], respectively;  $P=0.014$  for anti-MRSA antibiotic).

Table 5 Outcomes of the patients in which AST recommendation<sup>a</sup> was done.

| Outcome                                    | Accepted<br>(n=184) | Not accepted<br>(n=19) | P value |
|--------------------------------------------|---------------------|------------------------|---------|
| Clinical and microbiological outcome       |                     |                        |         |
| Favorable clinical response                | 165/184 (89.7)      | 14/19 (73.7)           | 0.056   |
| All-cause 30-day mortality                 | 2/184 (1.1)         | 2/19 (10.5)            | 0.045   |
| Infection-related 30-day mortality         | 1/184 (0.5)         | 0/19 (0)               | 1       |
| Microbiological persistence                | 13/58 (22.4)        | 1/4 (25)               | 1       |
| Microbiological recurrence                 | 10/72 (13.9)        | 1/7 (14.3)             | 1       |
|                                            |                     |                        |         |
| Length of hospital stay (day)              | 64 (44-134)         | 88 (48-171)            | 0.538   |
|                                            |                     |                        |         |
| Duration of carbapenem use (day)           | 8 (5-13)            | 14 (8-15)              | 0.026   |
| Duration of anti-MRSA antibiotic use (day) | 10 (5.3-15)         | 15.5 (13.8-45.3)       | 0.014   |

Data are presented as numbers (%) or medians (interquartile ranges).

<sup>a</sup> Recommendation includes choice of antibiotic and dose adjustment and excludes others such as recommendation of therapeutic drug monitoring (TDM) and addition of examination.

Abbreviations: AST, antimicrobial stewardship team; MRSA, methicillin-resistant *Staphylococcus aureus*.

## Discussion

To date, several studies regarding ASP, including recommendations for antibiotic discontinuation, change/de-escalation, addition, and dose adjustment, have been reported.<sup>7,16,22,25</sup> However, most of them have focused on antibiotic usage and have not investigated individual detailed clinical and microbiological outcomes other than 30-day mortality or length of hospital stay. To our knowledge, this is the first study to investigate the effects of interventions, such as discontinuation and change/de-escalation of carbapenems and anti-MRSA antibiotics, on detailed clinical and microbiological outcomes. Our results showed that our ASP could reduce the duration of carbapenem and anti-MRSA antibiotic use without worsening clinical and microbiological outcomes.

In our interventions, frequent recommendations were discontinuation and change of antibiotics (most frequent change for carbapenems was de-escalation), rather than performing TDM, also in interventions for anti-MRSA antibiotics (Table 1). This trend was consistent with other studies in which major recommendations were related to the choice of antibiotics.<sup>7,22</sup> A previous study investigated the safety and efficacy of de-escalating antibiotics<sup>26</sup>; *E. coli* was the most frequent pathogen, and second-generation cephalosporins (cefotiam, cefmetazole, and flomoxef) were mostly selected as definitive therapy, a trend consistent with our results (Table 3).

Several studies investigating the efficacy of ASP for broad-spectrum antibiotics, including carbapenems, have reported that there was no significant difference in all-cause and infection-related 30-day mortality between intervention and non-intervention groups, although it decreased numerically by intervention.<sup>12,16,17,21,22</sup> In contrast to these previous studies, the all-cause 30-day mortality was significantly reduced by intervention in our study (Table 5). A total of 4 patients died in two groups in the present study. In the accepted group, a patient died of an underlying disease (solid malignancy) and another patient died due to infection and an underlying disease (hematological malignancy). In the not accepted group, 2 patients died due to an underlying disease (hematological or solid malignancy). In the present study, severity of patients was numerically higher in the not accepted group than in the accepted group (SOFA score 4 and 2, respectively;  $P=0.064$ ; Table 2). This might have been the cause of the higher all-cause mortality in the not accepted group. In addition, there were few deaths in our study, which could have introduced bias. When we analyzed mortality as infection-related, no difference was found between the accepted and not accepted groups, consistent with the results of the previous studies.<sup>12,16,17,21,22</sup>

In the present study, higher favorable clinical responses were obtained by our intervention, although the difference was not significant. In our study, the proportion of

1 hematological malignancy was higher in the intervention-not accepted group (Table 2),  
2 which could be a confounding factor. However, even when hematological malignancy  
3 was excluded from our population, similar trends were observed; that is, lower all-cause  
4 mortality and higher favorable clinical responses were obtained by the intervention (data  
5 not shown). Most studies regarding ASP, including recommendations such as antibiotic  
6 discontinuation and change/de-escalation, have not investigated detailed clinical and  
7 microbiological outcomes.<sup>12,16,17,21,22</sup> These previous studies evaluated only mortality or  
8 length of hospital stay as outcomes. However, our present study also evaluated the  
9 clinical response, microbiological persistence and recurrence, and changes in WBC, CRP,  
10 and BT. In our ASP, the interventions did not worsen the clinical and microbiological  
11 outcomes. Furthermore, when interventions were divided categorically, discontinuation  
12 and change (most were de-escalation in the case of carbapenems) also did not worsen the  
13 outcomes (data not shown); other categories could not be compared because all were  
14 accepted.

15 This study has several limitations. This was a retrospective single-center study that  
16 included patients with different characteristics, especially with respect to hematological  
17 malignancy, febrile neutropenia, and concomitant therapy. Thus, we cannot exclude the  
18 possibility that the outcomes did not deteriorate by discontinuation or de-escalation due

1 to the different backgrounds of the patients. Additionally, the sample size was small, and  
2 confounding factors could not be removed by multivariate analysis. These limitations  
3 should be considered when interpreting our results.

4 In conclusion, to our knowledge, this is the first study to investigate the effects of  
5 interventions such as discontinuation and change/de-escalation of carbapenems and  
6 anti-MRSA antibiotics on detailed clinical and microbiological outcomes. Our results  
7 showed that our ASP could reduce the duration of carbapenem and anti-MRSA antibiotic  
8 use without worsening clinical and microbiological outcomes. These results suggest that  
9 the review and intervention for these antibiotics by AST is as effective as ASP.

## 11 **Acknowledgment**

12 This research did not receive any specific grant from funding agencies in the public,  
13 commercial, or not-for-profit sectors.

## References

1. Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH. An institutional review of antimicrobial stewardship interventions. *J Glob Antimicrob Resist* 2016;6:75–7. <https://doi.org/10.1016/j.jgar.2016.03.006>.
2. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. *Clin Infect Dis* 2006;42 Supplement 2:S82–9. <https://doi.org/10.1086/499406>.
3. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clin Infect Dis* 2009;49:1175–84. <https://doi.org/10.1086/605630>.
4. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007;44:159–77. <https://doi.org/10.1086/510393>.

- 1
- 2 5. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al.
- 3 Implementing an antibiotic stewardship program: guidelines by the Infectious
- 4 Diseases Society of America and the Society for Healthcare Epidemiology of
- 5 America. Clin Infect Dis 2016;62:e51–77. <https://doi.org/10.1093/cid/ciw118>.
- 6
- 7 6. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems.
- 8 Clin Microbiol Rev 2005;18:638–56.
- 9 <https://doi.org/10.1128/CMR.18.4.638-656.2005>.
- 10
- 11 7. Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, et al. Outcome
- 12 measurement of extensive implementation of antimicrobial stewardship in patients
- 13 receiving intravenous antibiotics in a Japanese university hospital. Int J Clin Pract
- 14 2012;66:999–1008. <https://doi.org/10.1111/j.1742-1241.2012.02999.x>.
- 15
- 16 8. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr, Prato BS.
- 17 Antibiotic optimization. An evaluation of patient safety and economic outcomes.
- 18 Arch Intern Med 1997;157:1689–94. <https://doi.org/10.1001/archinte.157.15.1689>.

- 1
- 2 9. Cheng VC, To KK, Li IW, Tang BS, Chan JF, Kwan S, et al. Antimicrobial
- 3 stewardship program directed at broad-spectrum intravenous antibiotics prescription
- 4 in a tertiary hospital. *Eur J Clin Microbiol Infect Dis* 2009;28:1447–56.
- 5 <https://doi.org/10.1007/s10096-009-0803-8>.
- 6
- 7 10. Cook PP, Gooch M. Long-term effects of an antimicrobial stewardship programme at
- 8 a tertiary-care teaching hospital. *Int J Antimicrob Agents* 2015;4:262–7.
- 9 <https://doi.org/10.1016/j.ijantimicag.2014.11.006>.
- 10
- 11 11. Bantar C, Sartori B, Vesco E, Heft C, Saúl M, Salamone F, et al. A hospital wide
- 12 intervention program to optimize the quality of antibiotic use: impact on prescribing
- 13 practice, antibiotic consumption, cost savings, and bacterial resistance. *Clin Infect*
- 14 *Dis* 2003;37:180–6. <https://doi.org/10.1086/375818>.
- 15
- 16 12. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care:
- 17 impact on resistance and clinical outcomes. *Am J Infect Control* 2012;40:526–9.
- 18 <https://doi.org/10.1016/j.ajic.2011.07.011>.

- 1
- 2 13. Lewis GJ, Fang X, Gooch M, Cook PP. Decreased resistance of *Pseudomonas*
- 3 *aeruginosa* with restriction of ciprofloxacin in a large teaching hospital's intensive
- 4 care and intermediate care units. Infect Control Hosp Epidemiol 2012;33:368–73.
- 5 <https://doi.org/10.1086/664763>.
- 6
- 7 14. Philmon C, Smith T, Williamson S, Goodman E. Controlling use of antimicrobials in
- 8 a community teaching hospital. Infect Control Hosp Epidemiol 2006;27:239–44.
- 9 <https://doi.org/10.1086/500419>.
- 10
- 11 15. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of
- 12 requiring prior authorization for selected antimicrobials: expenditures,
- 13 susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230–9.
- 14 <https://doi.org/10.1086/514545>.
- 15
- 16 16. Liew YX, Lee W, Loh JC, Cai Y, Tang SS, Lim CL, et al. Impact of an antimicrobial
- 17 stewardship programme on patient safety in Singapore General Hospital. Int J
- 18 Antimicrob Agents 2012;40:55–60.

1 <https://doi.org/10.1016/j.ijantimicag.2012.03.004>.

2  
3 17. Horikoshi Y, Higuchi H, Suwa J, Isogai M, Shoji T, Ito K. Impact of computerized  
4 pre-authorization of broad spectrum antibiotics in *Pseudomonas aeruginosa* at a  
5 children's hospital in Japan. J Infect Chemother 2016;22:532–5.  
6 <https://doi.org/10.1016/j.jiac.2016.05.001>.

7  
8 18. LaRocco A Jr. Concurrent antibiotic review programs—a role for infectious diseases  
9 specialists at small community hospitals. Clin Infect Dis 2003;37:742–3.  
10 <https://doi.org/10.1086/377286>.

11  
12 19. Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE. Is the  
13 “low-hanging fruit” worth picking for antimicrobial stewardship programs? Clin  
14 Infect Dis 2012;55:587–92. <https://doi.org/10.1093/cid/cis494>.

15  
16 20. Vettese N, Hendershot J, Irvine M, Wimer S, Chamberlain D, Massoud N. Outcomes  
17 associated with a thrice-weekly antimicrobial stewardship programme in a 253-bed  
18 community hospital. J Clin Pharm Ther 2013;38:401–4.

1 <https://doi.org/10.1111/jcpt.12079>.

2  
3 21. García-Rodríguez JF, Bardán-García B, Peña-Rodríguez MF, Álvarez-Díaz H,  
4 Mariño-Callejo A. Meropenem antimicrobial stewardship program: clinical,  
5 economic, and antibiotic resistance impact. Eur J Clin Microbiol Infect Dis  
6 2019;38:161–70. <https://doi.org/10.1007/s10096-018-3408-2>.

7  
8 22. Hagiwara D, Sato K, Miyazaki M, Kamada M, Moriwaki N, Nakano T, et al. The  
9 impact of earlier intervention by an antimicrobial stewardship team for specific  
10 antimicrobials in a single weekly intervention. Int J Infect Dis 2018;77:34–9.  
11 <https://doi.org/10.1016/j.ijid.2018.09.025>.

12  
13 23. Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT. The Sanford Guide  
14 to Antimicrobial Therapy.48th ed. Vermont: Antimicrobial Therapy;2018.

15  
16 24. Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochiai R et al. The Japanese  
17 guidelines for the management of sepsis. J Intensive Care2014;2:55.  
18 <https://doi.org/10.1186/s40560-014-0055-2>.

- 1 25. Niwa T, Shinoda Y, Suzuki A, Ohmori T, Ohta H, Fukao A, et al. Outcome  
2 measurement of the review system for appropriate use of antimicrobial injections in  
3 all inpatients established by the infection control team. *Iryo Yakugaku*  
4 2012;38:273–81. <https://doi.org/10.5649/jjphcs.38.273>.  
5  
6 26. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of  
7 bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients.  
8 *Infection* 2011;39:319–25. <https://doi.org/10.1007/s15010-011-0116-6>.  
9